Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens

European Journal of Immunology

Volumn 30, Issue 12, 2000, Pages 3522-3532

  Denkberg, Galit ^a   Cohen, Cyril J ^b   Segal, Dina ^a   Kirkin, Alexei F ^b   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Cancer peptide; MHC class I; MHC tetramer

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; RECOMBINANT ANTIGEN; TETRAMER; TUMOR ANTIGEN; VIRUS PROTEIN;

ARTICLE; CELL INCLUSION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ESCHERICHIA COLI; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; ESCHERICHIA COLI; GENE PRODUCTS, TAX; HLA-A2 ANTIGEN; HUMANS; MASS SPECTROMETRY; PROTEIN FOLDING; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034535585     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(2000012)30:12<3522::AID-IMMU3522>3.0.CO;2-D     Document Type: Article

References (43)

1. Ligand recognition by alpha beta T cell receptors
2. Peptides naturally presented and presentation
3. Mechanism of class I assembly with beta 2 microglobulin and loading with peptide
4. From TCR engagement to T cell activation: A kinetic view of T cell behaviour
5. Phenotypic analysis of antigen-specific T lymphocytes
6. High- and low-potency ligands with similar affinities for the TCR: The importance of kinetics in TCR signaling
7. Serial triggering of many T-cell receptors by a few peptide-MHC complexes
8. HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides
9. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic
10. In vitro induction of specific cytotoxic T lymphocyes using recombinant single-chain class I/peptide complexes
11. A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity
12. Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active β2-microglobulin domain
13. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells
14. The human class II MHC protein HLA-DR1 assembles as empty heterodimers in the absence of antigenic peptide
15. Formation of functional peptide complexes of class II major histocompatibility complex proteins from subunits produced in Escherichia coli
16. Production of soluble MHC class II proteins with covalently bound single peptides
17. Soluble class I MHC with β2 microglobulin covalently linked peptides: Specific binding to a T-cell hybridoma
18. Cell surface expression of class II MHC proteins bound by a single peptide
19. The repertoire of T cells shaped by a single MHC/peptide ligand
20. Creating CTL targets with epitope-linked β2-microglobulin constructs
21. Cancer vaccines based on the identification of genes encoding cancer regression antigens
22. T-cell-defined tumor antigens
23. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0201-binding residues
24. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
25. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: A 13 residue consensus peptide specifies biotinylation in Escherichia coli
26. Studies of fibronectin and its domains. II. Secondary structure and spatial configuration of fibronectin and its domains
27. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis
28. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules
29. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
30. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
31. HLA-peptide tetrameric complexes
32. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
33. + T cells during the primary immune response to Epstein-Barr virus in vivo
34. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
35. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes
36. + T cells in primary and secondary influenza pneumonia
37. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
38. Quantitative analysis of hepatitis C virus-specific CDS(+) T cells in peripheral blood and liver using peptide-MHC tetramers
39. + T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy
40. Creating and engineering human antibodies for immunotherapy
41. Recombinant antibody with the antigen specific, major histocompatibility complex-restricted specificity of T cells
42. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to MHC/peptide class I complexes with T-cell receptor-like specificity
43. The use of HLA/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire